Table 2.
Associations between hOGG1 polymorphisms and neuroblastoma susceptibility
| Genotype | Cases (N=512) |
Controls (N=1076) |
P a | Crude OR (95% CI) |
P | Adjusted OR (95% CI) b |
P b |
|---|---|---|---|---|---|---|---|
| rs1052133 G>C | |||||||
| GG | 197 (38.48) | 330 (30.67) | 1.00 | 1.00 | |||
| GC | 217 (42.38) | 567 (52.70) | 0.64 (0.51-0.81) | 0.0002 | 0.64 (0.51-0.81) | 0.0002 | |
| CC | 98 (19.14) | 179 (16.64) | 0.92 (0.68-1.24) | 0.576 | 0.92 (0.68-1.24) | 0.583 | |
| Additive | 0.0005 | 0.90 (0.77-1.04) | 0.155 | 0.90 (0.77-1.04) | 0.157 | ||
| Dominant | 315 (30.67) | 746 (69.33) | 0.002 | 0.71 (0.57-0.88) | 0.002 | 0.71 (0.57-0.88) | 0.002 |
| Recessive | 414 (80.86) | 897 (83.36) | 0.219 | 1.19 (0.90-1.56) | 0.219 | 1.19 (0.90-1.56) | 0.216 |
| rs159153 T>C | |||||||
| TT | 415 (81.05) | 858 (79.74) | 1.00 | 1.00 | |||
| TC | 94 (18.36) | 211 (19.61) | 0.92 (0.70-1.21) | 0.550 | 0.92 (0.70-1.21) | 0.553 | |
| CC | 3 (0.59) | 7 (0.65) | 0.89 (0.23-3.44) | 0.861 | 0.89 (0.23-3.46) | 0.866 | |
| Additive | 0.827 | 0.92 (0.72-1.19) | 0.540 | 0.92 (0.72-1.19) | 0.544 | ||
| Dominant | 97 (18.95) | 218 (20.26) | 0.539 | 0.92 (0.71-1.20) | 0.539 | 0.92 (0.71-1.20) | 0.543 |
| Recessive | 509 (99.41) | 1069 (99.35) | 0.879 | 0.90 (0.23-3.50) | 0.881 | 0.91 (0.23-3.52) | 0.886 |
| rs293795 A>G | |||||||
| AA | 462 (90.23) | 955 (88.75) | 1.00 | 1.00 | |||
| AG | 49 (9.57) | 116 (10.78) | 0.87 (0.61-1.24) | 0.450 | 0.87 (0.61-1.24) | 0.451 | |
| GG | 1 (0.20) | 5 (0.46) | 0.41 (0.05-3.55) | 0.421 | 0.42 (0.05-3.57) | 0.423 | |
| Additive | 0.538 | 0.85 (0.61-1.18) | 0.319 | 0.85 (0.61-1.18) | 0.321 | ||
| Dominant | 50 (9.77) | 121 (11.25) | 0.374 | 0.85 (0.60-1.21) | 0.374 | 0.86 (0.60-1.21) | 0.376 |
| Recessive | 511 (99.80) | 1071 (99.54) | 0.414 | 0.42 (0.05-3.60) | 0.428 | 0.42 (0.05-3.62) | 0.430 |
| Combined effect of protective genotypes | |||||||
| 0 | 180 (35.16) | 311 (28.90) | 1.00 | 1.00 | |||
| 1 | 230 (44.92) | 512 (47.58) | 0.78 (0.61-0.99) | 0.039 | 0.78 (0.61-0.99) | 0.039 | |
| 2 | 74 (14.45) | 186 (17.29) | 0.69 (0.50-0.95) | 0.024 | 0.69 (0.50-0.95) | 0.024 | |
| 3 | 28 (5.47) | 67 (6.23) | 0.72 (0.45-1.16) | 0.182 | 0.72 (0.45-1.17) | 0.184 | |
| 1-3 | 332 (64.84) | 765 (71.10) | 0.012 | 0.75 (0.60-0.94) | 0.012 | 0.75 (0.60-0.94) | 0.012 |
OR, odds ratio; CI, confidence interval. a χ2 test for genotype distributions between neuroblastoma patients and controls. b Adjusted for age and gender. c Protective genotypes were rs1052133 GC/CC, rs159153 TC/CC, rs293795 AG/GG.